The French-based pharmaceutical company Sanofi (NASDAQ: SNY) has been flying under the radar over the past few years as companies like AbbVie, Bristol Myers Squibb, and Merck have dominated the space through the tremendous success of their drugs. However, while it's still trading below its all-time highs, Sanofi is making moves to drive growth into the future -- so now might not be a bad time to look at adding the stock to your portfolio.
Image source: Getty Images.
Sanofi was actually a creation of several different companies, including Aventis, Synthélabo, Hoechst, Rhône-Poulenc Rorer, and several others. Through mergers and acquisitions (M&A) we got the Sanofi we know today. Sanofi has been best known for creating drugs like Menactra (meningitidis vaccine), Lantus (diabetes), Eloxatin (colorectal cancer), and Taxorete (prostate and breast cancer). But in the last few years, with drugs going off-patent and sales declining across its many products, Sanofi has been in a bit of a slump .
Source Fool.com